Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
Novartis’s nuclear vision starts to take shape
A radioligand acquired as part of a $2.1bn deal – and which the sellside believes to be Novartis’s most valuable R&D asset – hits in phase III.
Vaccine developers move to stay ahead of Covid-19 variants
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
